Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis
Clinical trial NCT02590588 · TERMINATED
Trial details
- NCT number
- NCT02590588
- Sponsor
- John Mark Sloan
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-01-01
- Primary completion
- 2017-03-27
- Enrollment
- 1
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.